Co-Authors
This is a "connection" page, showing publications co-authored by DIMPY KOUL and ERIK PHILIP SULMAN.
Connection Strength
0.699
-
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407.
Score: 0.178
-
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget. 2017 Mar 28; 8(13):21741-21753.
Score: 0.147
-
Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells. Cancer Res. 2014 Nov 15; 74(22):6731-2.
Score: 0.125
-
A high Notch pathway activation predicts response to ? secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells. 2014 Jan; 32(1):301-12.
Score: 0.118
-
PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A. 2017 10 24; 114(43):E9086-E9095.
Score: 0.038
-
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget. 2017 Aug 15; 8(33):54285-54296.
Score: 0.037
-
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 2013 Jul 01; 27(13):1462-72.
Score: 0.028
-
Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res. 2013 May 15; 73(10):3062-74.
Score: 0.028